La vendita allo scoperto per Passage Bio dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Passage Bio. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Passage Bio (NASDAQ:PASG) Azioni, Report sulle vendite allo scoperto

Passage Bio

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Passage Bio Inc

News

NGVC

Reported Earlier, Natural Grocers by Vitamin Cottage Names Richard Hallé As Chief Financial Officer, Effective January 1, 2025

Reported Earlier, Brookfield Realigns Corporate Structure, Unlocking Value In Asset Management With Broader Shareholder And Index Reach

Lavoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) reported quarterly sales of $1.888 billion which beat the analyst consensus estimate of $1.793 billion by 5.32 percent. This is a 4.95 percent increase over sales of $1.799 billion the same period last year.

Earnings

LVRO

Lavoro FY Sales $1.888B Beat $1.793B Estimate; Net Loss $154.6M Up From $43.7M YoY

The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities, and the injection process is expected on average to take about 15 seconds. As part of the subcutaneous autoinjector 360 mg weekly maintenance regimen under review, patients who have completed the biweekly intravenous (IV) initiation phase would receive weekly doses that maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils&#x2A; which can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been cleared from the brain.

BIIB

Reported Earlier, Eisai And Submit LEQEMBI BLA For Subcutaneous Alzheimer's Treatment To FDA, Targeting Early Disease Stages

Striking employees at Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) are poised to vote on a new contract proposal on Monday. The proposal, which includes a 38% wage increase over four years and a larger signing bonus, has received backing from the workers&#8217; union. 
What Happened: The International Association of Machinists and Aerospace Workers (IAM) stated that they have negotiated the best possible terms with Boeing. Previously, union members had turned down two offers from the company.
Reuters reported on Friday that this new offer comes as Boeing attempts to stabilize its finances amid a seven-week strike involving over 33,000 factory workers on the U.S. West Coast. The strike has significantly affected Boeing&#8217;s cash flow and halted production of key aircraft models.
Acting U.S. Secretary of Labor Julie Su facilitated recent negotiations, lauding both parties for their efforts. President Joe Biden also praised the union and Boeing for reaching a new contract proposal, highlighting the sacrifices made by Boeing&#8217;s machinists.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41642374/cathie-wood-shuffles-her-tech-deck-continues-dumping-tesla-and-palantir-stocks-up-on-amd-and-met?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Shuffles Her Tech Deck: Continues Dumping Tesla And Palantir, Stocks Up On AMD And Meta</a>
Boeing&#8217;s latest offer includes a $12,000 ratification bonus, integrating previous bonuses into workers&#8217; 401(k) retirement accounts. Despite the improved terms, approval remains uncertain as some workers express dissatisfaction due to the absence of a defined-benefit pension.
Why It Matters: The ongoing strike has already cost Boeing an <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41524809/boeing-strike-drags-on-union-contract-rejection-adds-further-uncertainty-costs-reco">estimated $2 billion</a> over the last five weeks. The machinists&#8217; rejection of previous offers has added further uncertainty to Boeing&#8217;s financial recovery efforts.
In a bid to bolster its finances, Boeing recently expanded its stock offering, aiming for a <a href="https://www.benzinga.com/markets/equities/24/10/41606547/boeing-eyes-20-7-billion-windfall-as-stock-offering-expands-details">$20.7 billion windfall</a>. The company priced its public offerings at 112.5 million shares of common stock at $143.00 each. 
Price Action: Boeing saw its stock climb higher by 2.77% during the after-hours market after it closed at $149.31 on Thursday, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41615718/cathie-woods-sky-high-vision-dumps-shares-of-cybercab-touting-tesla-for-this-evtol-play?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood&#8217;s Sky-High Vision: Dumps Shares Of Cybercab Touting Tesla For This eVTOL Play</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Equities

Markets

General

Boeing Sweetens Deal With 38% Wage Hike, $12K Bonus And More To End 7-Week Strike: Vote Set For Monday

SOBR

Reported Earlier, SOBRsafe Regains Nasdaq Compliance In Minimum Bid Price Requirement

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the &#8220;Fear&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Nasdaq Composite falling more than 500 points during the session. The S&amp;P 500 and Nasdaq both recorded their biggest single-day declines since Sept. 3.
Shares of Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) fell around 4% on Thursday after the company reported third-quarter financial results. Shares of Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) fell around 6% on Thursday after the company reported first-quarter financial results.
On the economic data front, U.S. initial jobless claims declined by 12,000 from the previous week to 216,000 in the week ending Oct. 26. The personal consumption expenditure price index rose 0.2% month-over-month in September following a 0.1% increase in August.
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, consumer discretionary, and real estate stocks recording the biggest losses on Thursday. However, utilities and energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 378 points to 41,763.46 on Thursday. The S&amp;P 500 fell 1.86% to 5,705.45, while the Nasdaq Composite fell 2.76% at 18,095.15 during Thursday's session.
Investors are awaiting earnings results from Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), and Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 43.5, the index moved to the &#8220;Fear&#8221; zone on Thursday, versus a prior reading of 54.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Trading Ideas

MSFT

S&P 500 Records Worst Session In Over A Month, Meta And Microsoft Tumble: Greed Index Moves To 'Fear' Zone

Macro Economic Events

Econ #s

Economics

U.K. Nationwide HPI (MoM) For October 0.1% Vs. 0.3% Est.; 0.6% (Revised) Prior

U.K. Nationwide HPI (YoY) For October 2.4% Vs. 2.8% Est.; 3.2% Prior

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) to report quarterly earnings at $2.43 per share on revenue of $48.99 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Chevron shares fell 0.5% to $148.04 in after-hours trading.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) reported better-than-expected earnings and sales results for the fourth quarter. The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share. Apple shares fell 1.8% to $221.74 in the after-hours trading session.</li>
<li>Analysts are expecting Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) to post quarterly earnings at $1.88 per share on revenue of $93.94 billion. The company will release earnings before the markets open. Exxon Mobil shares fell 0.04% to $116.73 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) posted stronger-than-expected results for the third quarter on Thursday. Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year. Amazon shares jumped 6% to $197.50 in the after-hours trading session.</li>
<li>Analysts expect Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) to report quarterly earnings at $1.62 per share on revenue of $50.9 billion before the opening bell. Cardinal Health shares gained 0.1% to $108.65 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

AAPL

AMZN

Apple, Amazon And 3 Stocks To Watch Heading Into Friday

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) cost of making the entire Cybercab will roughly equal Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Waymo&#8216;s cost for installing lidar sensors on its robotaxis, according to Ark Invest analyst Brett Winton.
What Happened: The cost of manufacturing the Tesla Cybercab should be half the cost of manufacturing the company&#8217;s Model 3 or Model Y given the Cybercab has half the content as the other vehicles, Winton said. So once production reaches scale, the cost of manufacturing a Cybercab should be nearly $18,000, according to the analyst.
The cost of purchasing Waymo&#8217;s lidar sensors together with installation charges will cost roughly the same amount, Winton said. While the cost of the lidars alone would come at $13,500, installation and wiring will cost another $1,500, taking the total cost of the lidar sensors alone to $15,000.
Waymo installs its sensor suite on electric vehicles made by auto manufacturers such as Zeekr, implying a separate cost for purchasing the vehicle.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">tophat lidar at $7.5k, on-body lidars at $2k &#x2A; 3. Call it $1.5k to install the parts and wiring: $15k cybercab at ~half the content of the average model 3/y should be ~half as expensive to manufacture, scaled. Suggests $18k.
&mdash; Brett Winton (@wintonARK) <a href="https://twitter.com/wintonARK/status/1852047930582274310?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Winton is not alone in expecting the cost of making the Cybercab to be lower than Waymo&#8217;s cost for deploying its robotaxis. 
"ARK estimates that Waymo&#8217;s vehicles cost more than $100,000 to produce, its sensor set alone ~$40,000+, though it is working to reduce costs. Tesla&#8217;s Model 3 costs $40,000, sensors included. While it needs to build backend support for remote vehicle assistance and customer support, Tesla should be able to leverage its existing factory, charging, and service infrastructure to scale efficiently," Ark Invest&#8217;s Tasha Keeney also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41247281/teslas-robotaxi-platform-could-account-for-90-of-ev-giants-enterprise-value-over-th">said in a blog post</a> last month.
Why It Matters: Tesla unveiled its Cybercab with no pedals or steering wheel last month. The vehicle, CEO Elon Musk then said, will enter production &#8220;before 2027&#8221; and be priced below $30,000.
During Tesla&#8217;s third-quarter earnings call last month, Musk said that the company expects to start a ride-hail service in Texas and California starting next year, <a href="https://www.benzinga.com/news/24/10/41484511/palo-alto-may-open-streets-to-tesla-robotaxis-but-california-regulators-will-decide-fate" target="_blank" rel="noreferrer noopener">subject to regulatory approval</a>, with self-driving Model 3 and Model Y vehicles.
However, the vehicles might not all operate as driverless robotaxis initially but with a driver as some states demand it until the company touches certain milestones in terms of miles and hours driven, the company then said.
However, Musk also expressed confidence about the&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41279865/elon-musk-may-unveil-teslas-robotaxi-but-consumers-respond-with-ehhh-new-study-reveals-skepticism-ne" target="_blank" rel="noreferrer noopener">company operating driverless paid rides sometime next year</a>, placing it as a firm competitor to Alphabet Inc&#8217;s Waymo. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41617327/lucid-to-start-taking-orders-for-gravity-suv-next-week-but-only-for-premium-variant-priced-at-about" target="_blank" rel="noreferrer noopener">Lucid To Start Taking Orders for Gravity SUV Next Week, But Only For Premium Variant Priced At About $95,000</a></li>
</ul>
Photos courtesy: Tesla and Shutterstock

Tech

GOOG

GOOGL

TSLA

Tesla Can Make Cybercab For The Same Money It Takes Waymo To Install Lidar Sensors On Its Robotaxi, Says Ark Analyst

On Thursday, influential economist&nbsp;Peter Schiff&nbsp;took a swipe at&nbsp;MicroStrategy Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) CEO Michael Saylor&#8217;s&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil">$42 billion</a> Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investment strategy, likening it to a market trap.
What Happened: Schiff took to X, formerly Twitter, and compared Saylor to &#8220;the Egg Man&#8221; in a metaphorical critique of his Bitcoin investment plans.
Schiff used an egg futures analogy to express his concerns about Saylor&#8217;s strategy. He suggested that MicroStrategy could end up holding a large amount of Bitcoin with no potential buyers, should the market turn.
&#8220;Sell to whom, you&#8217;re the&nbsp;egg man!&#8221; Schiff concluded, implying that Saylor&#8217;s aggressive Bitcoin buying could potentially trap the company in a volatile market.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41606588/if-you-invested-1-000-in-dogecoin-on-jan-1-2021-heres-how-much-youd-have-today?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If You Invested $1,000 In Dogecoin On Jan. 1, 2021, Here&#8217;s How Much You&#8217;d Have Today</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Michael Saylor is the Egg Man. His latest announcement is that <a href="https://twitter.com/search?q=%24MSTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MSTR</a> will spend another $42 billion to buy <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>, funded by issuing $21 billion in debt and $21 billion in equity over the next three years. This reminds me of a joke I heard a long time ago. A client calls his…
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1852004824973185363?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Saylor&#8217;s Bitcoin strategy has been a hot topic in the financial world. Last month, he announced that MicroStrategy plans to invest an additional $42 billion in Bitcoin over the next three years,&nbsp;funded by issuing $21 billion&nbsp;in debt and $21 billion&nbsp;in equity.
Other companies like&nbsp;Coinbase Global Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) have also shown interest in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41645548/coinbase-on-following-microstrategys-bitcoin-playbook-looking-for-opportunities-says-cfo-b">expanding their cryptocurrency investment</a> portfolios.
Coinbase CFO Alesia Haas on Thursday said that the company holds a cryptocurrency investment portfolio on its balance sheet, valued at approximately $1.3 billion at the close of the third quarter.
This portfolio represented close to 25% of Coinbase&#8217;s total cash reserves.
Meanwhile, Bitcoin ETFs are edging closer to becoming the <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41629253/satoshi-nakamoto-could-soon-be-surpassed-by-blackrock-grayscale-as-top-bitcoin-holder">largest collective holder of Bitcoin</a>, potentially surpassing Satoshi Nakamoto&#8217;s legendary holdings.
Price Action: On Thursday, MicroStrategy shares ended the day 1.1% lower at $244.50 and gained 0.7% in the after-hours trading. Bitcoin was seen trading 4.1% lower at $69,321.65, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41609877/bitcoin-flirts-with-all-time-high-ethereum-dogecoin-surge-stay-tuned-says-trader-who-sees-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Flirts With All-Time High, Ethereum, Dogecoin Surge: &#8216;Stay Tuned,&#8217; Says Trader Who Sees &#8216;Only One Untagged High Left&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

MSTR

Michael Saylor The 'Egg Man'? Peter Schiff Points Out A Potential Pitfall Of MicroStategy's $42B Debt-Funded Bitcoin Bet

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens
&nbsp;A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed the single-agent enzalutamide control arm performing better than historical controls and similar to the combination of masofaniten and enzalutamide and therefore, unlikely to achieve the primary endpoint of the study&nbsp;
Additional clinical studies with masofaniten including the combination study with abiraterone acetate and apalutamide as well as the remaining investigator sponsored trials will also be terminated and the IND and CTAs in different geographies will be withdrawn
Company will initiate a process to explore and review strategic options focused on maximizing shareholder value

EPIX

Reported Earlier, ESSA Pharma Terminates Phase 2 Study Evaluating Masofaniten Combined With Enzalutamide In Patients With mCRPC

ZEEKR delivered 25,049 vehicles in October 2024, a 92% year-over-year increase. Year-to-date, ZEEKR has delivered 167,922 vehicles in 2024, representing 82% growth over the same period last year. As of the end of October 2024, ZEEKR's cumulative deliveries reached 364,555.

Reported Earlier, ZEEKR Delivered 25,049 Vehicles In October, Up By 92% YoY

Financial and Operational Summary for the Fiscal Year Ended June 30, 2024
<ul>
<li>Revenues increased by approximately RMB 41.6 million (US$5.7 million), or 29% to approximately RMB 183.7 million (US$25.3 million) for the fiscal year ended June 30, 2024 from approximately RMB 142.1 million for the fiscal year ended June 30, 2023.</li>
<li>Gross profit increased by approximately RMB 16.1 million (US$2.2 million), or 28% to approximately RMB 74.8 million (US$10.3 million) for the fiscal year ended June 30, 2024 from approximately RMB 58.6 million for the fiscal year ended June 30, 2023.</li>
<li>Income from operations in the fiscal year ended June 30, 2024 of approximately RMB 10.1 million ($1.4 million), compared to a loss from operations of approximately RMB 44.5 million in the same period of 2023.</li>
<li>The Company increased selling expenses by approximately 40%, and research &amp; development (R&amp;D) by approximately 56% compared to the same period in 2023. Management expects this investment to drive returns in the form of increased revenue in the coming quarters.</li>
<li>Development of B Channels showed strong growth. As of June 30, 2024, Zhibao grew the number of B channels the Company works with from approximately 1,550 to nearly 1,800. B channels are distributed amongst diverse market segments and is a key component to growing our 2B2C embedded digital insurance model.</li>
<li>As of June 30, 2024, the Company reached and served in excess of 15 million end customer users, which management expects will continue to drive revenue in the coming years.</li>
</ul>

ZBAO

Zhibao Technology FY24 Revenue $25.27M Up 29% YoY, EPS $0.06

Reported Earlier, Fujitsu And AMD Join Forces For Sustainable AI Computing, To Accelerate Open-Source Innovations

FUJHY

Subaru H1 Revenue ¥2,266.2B Up From ¥2,213.5B YoY, EPS ¥219.08 Up From ¥198.58 YoY

Reported Earlier, China Caixin Manufacturing Purchasing Managers Index For October 50.3 Vs. 49.7 Est.; 49.3 Prior

Reported Earlier, Australia Producer Price Index (QoQ) For Q3 0.9% Vs. 0.7% Est.; 1.0% Prior

Reported Earlier, Australia Producer Price Index (YoY) For Q3 3.9% Vs. 4.8% Prior

Passage Bio gains after licensing deal with GEMMA Bio

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Passage Bio (PASG – Research Report), Regeneron (R...

Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)

Passage Bio (PASG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Whitney Ijem from Ca...

Positive Outlook for Passage Bio: Strategic Financial Moves and Promising Clinical Prospects Boost Buy Rating

Passage Bio GAAP EPS of -$0.26

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Passage Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pasg-stock-quote/">PASG</a>) just reported results for the second quarter of 2024.<ul><li>Passage Bio reported earnings per share of -26 cents. This was above the analyst estimate for EPS of -31 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pasg-stock-earnings-passage-bio-for-q2-of-2024/">PASG Stock Earnings: Passage Bio Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PASG Stock Earnings: Passage Bio Beats EPS for Q2 2024

TD Cowen analyst Brendan Smith has maintained their bullish stance on PASG stock, giving a Buy rating on August 1. Brendan Smith has given his Buy ...

Buy Rating Affirmed for Passage Bio on Strong Cost Control and Promising Clinical Trials

Passage Bio ( ($PASG) ) has provided an announcement. Passage Bio, Inc. enhanced its leadership team by appointing Thomas Kassberg, a seasoned exec...

Passage Bio Appoints Thomas Kassberg to Leadership Team

An update from Passage Bio ( ($PASG) ) is now available. Passage Bio Inc. presented promising interim data from their upliFT-D clinical trial at th...

Passage Bio Reveals Promising Gene Therapy Trial Results

Whitney Ijem, an analyst from Canaccord Genuity, maintained the Buy rating on Passage Bio (PASG – Research Report). The associated price target rem...

Optimistic Buy Rating for Passage Bio as PBFT02 Shows Promising Results and Market Potential

Passage Bio (PASG) announced the company delivered preclinical and interim clinical data as part of an oral presentation at the European Society of...

Passage Bio delivered preclinical, interim data at ESGCT

PASG

REGN

Press Releases

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Health Care

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Financing

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Management

Passage Bio Welcomes Tom Kassberg to Board of Directors

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Comments

Passage Bio

Vendite allo scoperto

Passage Bio (NASDAQ:PASG) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO